Olmesartan

Olpress, Plaunac e altri

Bibliografia - Quali fonti bibliografiche per Olmesartan?

1. Agenzia Italiana del Farmaco – AIFA, Olpress – Riassunto Caratteristiche di Prodotto, 2021, 29 aprile https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000734_036026_RCP.pdf&retry=0&sys=m0b1l3


2. Al-Majed A.A. et al., Profiles Drug Subst. Excip. Relat. Methodol., 2017, 42, 241.


3. Georgaki-Angelaki E. et al., NDT Plus., 2009, 2 (4), 295.


4. Bangalore S. et al., BMJ, 2011, 342, d2234.


5. Bavbek N. et al., Ren. Fail., 2010, 32 (9), 1115.2010.


6. Bohm M. et al., Curr. Med. Res. Opin., 2006, 22 (7), 1375.


7. Brunner H.R., J. Hum. Hypertens., 2002, 16 Suppl. 2, S13.


8. Brunner H.R. et al., Clin. Drug Invest., 2003, 23 (7), 419.


9. Carter-Storch R. et al., Can. J. Cardiol., 2024, doi: 10.1016/j.cjca.2024.03.009.


10. Charfi O. et al., Curr. Drug Saf., 2019, 14 (1), 77.


11. Chrysant S.G. et al., Am. J. Hypertens., 2004, 17 (3), 252.


12. Chrysant S.G. et al., Blood Press. Monit., 2006, 11 (3), 135.


13. Chrysant S.G. et al., Clin. Ther., 2008, 30 (4), 587.


14. Chrysant S.G. et al., J. Hum. Hypertens., 2010, 24 (11), 730.


15. Chrysant S.G. et al., J. Am. Soc. Hypertens., 2012, 6 (2), 132.


16. Derosa G. et al., J. Clin. Pharm. Ther., 2013, 38 (1), 48.


17. Derosa G. et al., Clin. Exp. Hypertens., 2013a, 35 (5), 301.


18. Derosa G. et al., J. Am. Soc. Hypertens., 2013b, 7 (1), 32.


19. Derosa G. et al., Inflammation, 2014, 37 (1), 154.


20. Derosa G. et al., Eur. J. Pharm. Scie., 2014a, 51, 26.


21. Duerr M. et al., Clin. J. Am. Soc. Nephrol., 2010, 5 (4), 703.


22. Elgendy I.Y. et al., Am. J. Hypertens., 2015,28 (5), 576.


23. Food and Drug Administration – FDA, FDA Drug safety Communication: safety Review Update of Benicar (olmesartan) and cardiovascular events, 2011, 14 April https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-review-update-benicar-olmesartan-and-cardiovascular-events (accesso: marzo 2024).


24. Food and Drug Administration – FDA, Benicar – Prescribing Information, 2019, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021286s040lbl.pdf (accesso: aprile 2024).


25. Gardner S.F., Franks A.M., Ann. Pharmacother., 2003, 37 (1), 99.


26. Georgaki-Angelaki E. et al., NDT Plus, 2009, 2 (4), 295.


27. Haller H. et al., NEJM, 2011, 364 (10), 907.


28. Hazan L. et al., Hypertension, 2010, 55 (6), 1323.


29. He L., et al., J. Clin. Pharmacol., 2014, 54 (1), 61.


30. Ianiro G. et al., Aliment. Pharmacol. Ther., 2014, 40 (1), 16.


31. Kario K. et al., J. Hum. Hypertens., 2013, 27 (12), 721.


32. Kumbla D.K. et al., Indian Heart J., 2014, 66 (3), 340.


33. LactMed, Olmesartan, 2023, 15 August https://www.ncbi.nlm.nih.gov/books/NBK501627/ (accesso: marzo 2024).


34. Laeis P. et al., J. Hypertens. Suppl., 2001, 19 (1), S21.


35. Li K.Y. et al., Curr. Ther. Res.. Clin. Exp., 2014, 76, 7.


36. LiverTox, Olmesartan, 2017, 13 January https://www.ncbi.nlm.nih.gov/books/NBK548153/ (accesso: marzo 2024).


37. Ma S.F. et al., Drug Metab. Dispos., 2005, 33 (12), 1911.


38. Martinovic J et al., Lancet, 2001, 358 (9277), 241.


39. Menne J. et al., J. Am. Heart Assoc., 2014, 3 (2), e000810.


40. National Institutes of Health, Clinicaltrials.gov https://www.clinicaltrials.gov/study/NCT00141453 (accesso: marzo 2024).


41. Neutel J. M. et al., Am. J. Cardiol., 2001, 87 Suppl. 8A, 37C.


42. Ogihara T. et al., J. Hypertens., 2014, 32 (10), 2054.


43. Omboni S. et al., Drugs Aging, 2012, 29 (12), 981.


44. Oparil S. et al., J. Clin. Hypertens. (Greenwich), 2001, 3 (5), 283.


45. Oparil S. et al., Clin. Ther., 2010, 32 (7), 1252.


46. Parker S.C. et al., Med. J. Aust., 2001, 175 (3), 149.


47. Parving H.H. et al., Nephrol. Dial. Transplant., 2009, 24 (5), 1663.


48. Pickering T.G. et al., J. Am. Soc. Hypertens., 2010, 4 (2), 56.


49. Puchler K. et al., J. Hypertens. Suppl., 2001, 19 (1), S41,


50. Quan A., Early Hum. Dev., 2006, 82 (1), 23.


51. Ruilope L., Schaefer A., Adv. Ther., 2013, 30 (12), 1086.


52. Ruilope L., J. Clin. Hypertens. (Greenwich), 2016, 18 (6), 528.


53. Sakata Y. Eur. Heart J., 2015, 36 (15), 915.


54. Salimova M. et al., Neurotoxicol. Teratol., 2023, 98, 24.


55. Schiepatti A. et al., Aliment. Pharmacol. Ther., 2024, 59 (4), 432.


56. Schwoncho L.R., Manson H.N., J. Clin. Pharmacol., 2001, 41, 515.


57. Sen S. et al., Ther. Adv. Chronic Dis., 2013, 4 (5), 232.


58. Sievers P. et al., Drug Des. Devel. Ther., 2015, 9, 3935.


59. Smith D.H. et al., Am. J. Cardiovasc. Drugs, 2005, 5 (1), 41.


60. Stumpe K.O., Ludwig M., J. Hum. Hypertens., 2002, 16 Suppl. 2, S24.


61. Tanaka H. et al., Clin. Exp. Nephrol., 2009, 13 (1), 61.


62. Volpe M. et al., Adv. Ther., 2014, 31 (5), 561.


63. Von Bergmann K. et al., J. Hypertens Suppl., 2001, 19 (1), S33.


64. Wells T.G. et al., Paediatr. Drugs, 2012, 14 (6), 401.


65. Zhang X. et al., Cardiol. Ther., 2017, 6 (1), 13.